- Record: found
- Abstract: not found
- Article: not found
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria ,
Peter A Prieto ,
Michael T Tetzlaff ,
Alexandre Reuben ,
Miles C Andrews ,
Merrick I Ross ,
Isabella C Glitza ,
Janice Cormier ,
Wen-Jen Hwu ,
Hussein A Tawbi ,
Sapna P Patel ,
Jeffrey E Lee ,
Jeffrey E Gershenwald ,
Christine N Spencer ,
Vancheswaran Gopalakrishnan ,
Roland Bassett ,
Lauren Simpson ,
Rosalind Mouton ,
Courtney W Hudgens ,
Li Zhao ,
Haifeng Zhu ,
Zachary A Cooper ,
Khalida Wani ,
Alexander Lazar ,
Patrick Hwu ,
Adi Diab ,
Michael K Wong ,
Jennifer L McQuade ,
Richard Royal ,
Anthony Lucci ,
Elizabeth M Burton ,
Sangeetha Reddy ,
Padmanee Sharma ,
James Allison ,
Phillip A Futreal ,
Scott E Woodman ,
Michael A Davies ,
Jennifer A Wargo
February 2018
February 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Dual BRAF and MEK inhibition produces a response in a large number of patients with
stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical
stage III melanoma is upfront surgery and consideration for adjuvant therapy, which
is insufficient to cure most patients. Neoadjuvant targeted therapy with BRAF and
MEK inhibitors (such as dabrafenib and trametinib) might provide clinical benefit
in this high-risk p opulation.